Detail akcie Applied Therptcs Rg online

Business Summary: Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Financial Summary: BRIEF: For the three months ended 31 March 2025, Applied Therapeutics Inc revenues decreased from $190K to $0K. Net loss decreased 74% to $21.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Change in fair value of warrant liabilit increase from $63.4M (expense) to $3.1M (income).